Comparison of outcomes of second-line durvalumab plus tremelimumab versus lenvatinib following first-line atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.
Saved in:
| Title: | Comparison of outcomes of second-line durvalumab plus tremelimumab versus lenvatinib following first-line atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. |
|---|---|
| Authors: | Nishioka, Chinatsu1 (AUTHOR), Tahata, Yuki1 (AUTHOR), Maesaka, Kazuki1 (AUTHOR), Kai, Machiko1 (AUTHOR), Shirai, Kumiko1 (AUTHOR), Murai, Kazuhiro1 (AUTHOR), Makino, Yuki1 (AUTHOR), Saito, Yoshinobu1 (AUTHOR), Nozaki, Yasutoshi2 (AUTHOR), Nakabori, Tasuku3 (AUTHOR), Ishida, Hisashi4 (AUTHOR), Yakushijin, Takayuki5 (AUTHOR), Iio, Sadaharu6 (AUTHOR), Tatsumi, Nobuyuki7 (AUTHOR), Imanaka, Kazuho8 (AUTHOR), Kakita, Naruyasu9 (AUTHOR), Sakamori, Ryotaro10 (AUTHOR), Hosui, Atsushi11 (AUTHOR), Miyazaki, Masanori12 (AUTHOR), Matsumoto, Kengo13 (AUTHOR) |
| Source: | PLoS ONE. 5/7/2026, Vol. 21 Issue 5, p1-14. 14p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 19326203 |
|---|---|
| DOI: | 10.1371/journal.pone.0341395 |
